Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2025.Jun.26

Announcement on behalf of OBIGEN that it has submitted the application of its two pivotal phase 3 studies for OBI-858 to TFDA

2025.Jun.23

OBI has submitted the IND application of a Phase I/II human clinical trial for OBI-902 TROP2 ADC to the TFDA

2025.Jun.18

Announcement on behalf of Amaran of important resolutions of the 2025 Annual General Shareholders’ meeting.

2025.Jun.06

OBI's GlycOBI has attracted an international collaborator, TegMine Therapeutics, for the co-development of novel Antibody-Drug Conjugates

2025.May.20

Announcement on behalf of OBIGEN of resolution to lift the non-competition restrictions for directors

2025.May.20

Announcement on behalf of OBIGEN of important resolutions of 2025 Annual Shareholders’ meeting and accumulated losses amounting to 50% of paid-in capital

2025.May.12

The Board of Directors resolved to issue new common shares by private placement

2025.May.12

The Company's Board of Directors resolved to convene the 2025 Annual General Shareholders' Meeting (Additional matters)

2025.May.12

The BOD resolved to rename the Audit Committee to the Audit and Risk Management Committee

2025.May.12

The BOD resolved to rename the Remuneration Committee to the Remuneration and Nomination Committee

News

Latest News

Events

Latest events